索托克拉上市申请获受理 百济神州又一款血液肿瘤自研产品有望面市

中国网财经
29 Apr

中国网财经4月29日讯 昨日,国家药监局(NMPA)药品审评中心(CDE)正式受理百济神州在研BCL2抑制剂索托克拉片(sonrotoclax)的新药上市申请(NDA),并已纳入优先审评程序,拟用于治疗既往接受过治疗的慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)成人患者。索托克拉是百济神州自主研发的新一代BCL2抑制剂,也是百济神州继泽布替尼之后有望面市的又一款血液肿瘤的自研产品,或将...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10